Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Cohort 1: To estimate the Overall Response Rate (ORR) when a dose of 105 mg/m2 LY2606368 every 14 days is administered to patients with ED-SCLC that have platinum-sensitive disease. Cohort 2: To estimate the ORR when a dose of 105 mg/m2 LY2606368 every 14 days is administered in patients with Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC) that have platinum resistant/refractory disease.
Critère d'inclusion
- Extensive Disease Small Cell Lung Cancer